Sunil Healthcare Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 396654,
    "name": "Sunil Healthcare",
    "stock_name": "Sunil Healthcare",
    "full_name": "Sunil Healthcare Ltd",
    "name_url": "stocks-analysis/sunil-healthcare",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "67.37",
    "chg": -1.07,
    "chgp": "-1.56%",
    "dir": -1,
    "prev_price": "68.44",
    "mcapval": "69.09 Cr",
    "mcap": "Micro Cap",
    "scripcode": 537253,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE671C01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "647 ",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/sunil-healthcare-396654-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Sunil Healthcare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sunil-healthcare-fallingrising-3702377",
        "imagepath": "",
        "date": "2025-11-14 22:06:59",
        "description": "As of 14-Nov, Sunil Healthcare Ltd's stock price is currently at 72.00, reflecting an increase of 0.27 (0.38%). The stock has recently experienced a trend reversal, gaining after five consecutive days of decline. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally bearish trend. Despite this, the company has reported positive financial results, including a 9.89% growth in net profit and strong operating cash flow, which may have contributed to the recent uptick in stock price. Nonetheless, the stock has underperformed significantly over the past year, with a return of -5.26%, and has shown weak long-term fundamental strength, including a low return on capital employed and poor sales growth.\n\nIn the broader market context, the stock's performance over the past week has been notably poor, with a decline of 4.38%, while the benchmark Sensex has i..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3683839",
        "imagepath": "",
        "date": "2025-11-10 08:07:28",
        "description": "As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE Ratio of 44.63, an EV to EBITDA of 11.04, and a PEG Ratio of 0.19. These ratios suggest that the stock is priced high relative to its earnings growth potential.\n\nIn comparison to its peers, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla, rated as attractive, has a PE Ratio of 22.33 and an EV to EBITDA of 5.58. These figures highlight that Sunil Healthcare is trading at a premium compared to more attractively valued competitors. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.46% compared to the Sensex's 6.50%. This further reinforces the view that Sunil Healthcare may be overvalued in the current marke..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3682626",
        "imagepath": "",
        "date": "2025-11-09 08:07:04",
        "description": "As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19, which suggests that while the stock is expensive relative to earnings, it may offer growth potential at a reasonable price.\n\nIn comparison to its peers, Sunil Healthcare's PE ratio is higher than Sun Pharma Industries, which is considered expensive at 35.17, but lower than Divi's Laboratories, which is very expensive at 71.11. Additionally, Cipla, rated attractive, has a significantly lower PE ratio of 22.33, indicating that Sunil Healthcare may not be the best value in its sector. The company's recent stock performance has lagged behind the Sensex, particularly over the past year, where it has declined by 11.93% compared to a 4.62..."
      },
      {
        "title": "Is Sunil Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-sunil-healthcare-overvalued-or-undervalued-3681753",
        "imagepath": "",
        "date": "2025-11-08 08:06:48",
        "description": "As of 7 November 2025, the valuation grade for Sunil Healthcare has moved from attractive to fair. The company is currently fairly valued. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19. In comparison to peers, Sun Pharma has a PE ratio of 35.17 and is considered expensive, while Cipla, which is rated attractive, has a PE ratio of 22.33.\n\nDespite the recent downgrade in valuation, Sunil Healthcare's stock has shown resilience with a 1-week return of 4.58%, outperforming the Sensex, which had a return of -0.86%. However, over the longer term, the company has underperformed, with a 1-year return of -11.93% compared to the Sensex's 4.62%. This suggests that while the company is currently fairly valued, its long-term performance may warrant further scrutiny...."
      }
    ],
    "total": 86,
    "sid": "396654",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/sunil-healthcare-396654"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (LODR) Regulations 2015",
      "datetime": "28-Jan-2026",
      "details": "Sunil Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve Intimation of Board Meeting scheduled to be held on 6th February 2026 to consider interalia un-audited financial results (standalone and consolidated) for the 3rd quarter/9 months ended 31.12.2025 of FY 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "07-Jan-2026",
      "details": "Compliance certificate under Regulation 74(5) of SEBI (DP) regulations 2018 for quarter ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "29-Dec-2025",
      "details": "Trading window of the Company shall remain close from January 01 2026 till 48 hours after the declaration of the un-audited financial results for the 3rd quarter/nine months of financial year 2025-26 ended on 31st December 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Sunil Healthcare falling/rising?

2025-11-14 22:06:59

As of 14-Nov, Sunil Healthcare Ltd's stock price is currently at 72.00, reflecting an increase of 0.27 (0.38%). The stock has recently experienced a trend reversal, gaining after five consecutive days of decline. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally bearish trend. Despite this, the company has reported positive financial results, including a 9.89% growth in net profit and strong operating cash flow, which may have contributed to the recent uptick in stock price. Nonetheless, the stock has underperformed significantly over the past year, with a return of -5.26%, and has shown weak long-term fundamental strength, including a low return on capital employed and poor sales growth. In the broader market context, the stock's performance over the past week has been notably poor, with a decline of 4.38%, while the benchmark Sensex has i...

Is Sunil Healthcare overvalued or undervalued?

2025-11-10 08:07:28

As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, with a PE Ratio of 44.63, an EV to EBITDA of 11.04, and a PEG Ratio of 0.19. These ratios suggest that the stock is priced high relative to its earnings growth potential. In comparison to its peers, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla, rated as attractive, has a PE Ratio of 22.33 and an EV to EBITDA of 5.58. These figures highlight that Sunil Healthcare is trading at a premium compared to more attractively valued competitors. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -3.46% compared to the Sensex's 6.50%. This further reinforces the view that Sunil Healthcare may be overvalued in the current marke...

Is Sunil Healthcare overvalued or undervalued?

2025-11-09 08:07:04

As of 7 November 2025, Sunil Healthcare's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19, which suggests that while the stock is expensive relative to earnings, it may offer growth potential at a reasonable price. In comparison to its peers, Sunil Healthcare's PE ratio is higher than Sun Pharma Industries, which is considered expensive at 35.17, but lower than Divi's Laboratories, which is very expensive at 71.11. Additionally, Cipla, rated attractive, has a significantly lower PE ratio of 22.33, indicating that Sunil Healthcare may not be the best value in its sector. The company's recent stock performance has lagged behind the Sensex, particularly over the past year, where it has declined by 11.93% compared to a 4.62...

Is Sunil Healthcare overvalued or undervalued?

2025-11-08 08:06:48

As of 7 November 2025, the valuation grade for Sunil Healthcare has moved from attractive to fair. The company is currently fairly valued. Key ratios include a PE ratio of 44.63, an EV to EBITDA of 11.04, and a PEG ratio of 0.19. In comparison to peers, Sun Pharma has a PE ratio of 35.17 and is considered expensive, while Cipla, which is rated attractive, has a PE ratio of 22.33. Despite the recent downgrade in valuation, Sunil Healthcare's stock has shown resilience with a 1-week return of 4.58%, outperforming the Sensex, which had a return of -0.86%. However, over the longer term, the company has underperformed, with a 1-year return of -11.93% compared to the Sensex's 4.62%. This suggests that while the company is currently fairly valued, its long-term performance may warrant further scrutiny....

View All News